期刊: CLINICAL CANCER RESEARCH, 2023; 29 (7)
Purpose: ALK-activating mutations are identified in approxi-mately 10% of newly diagnosed neuroblastomas and ALK ampli-fications in a further 1%-2% of......
期刊: CLINICAL CANCER RESEARCH, 2023; 29 (7)
Purpose: Circulating tumor DNA (ctDNA) has emerged as a promising tumor-specific biomarker in pancreatic cancer, but current evidence of the clinical ......
期刊: CLINICAL CANCER RESEARCH, 2023; 29 (10)
Purpose: The final analyses of the INSIGHT phase II study evaluating tepotinib (a selective MET inhibitor) plus gefitinib versus chemotherapy in patie......
期刊: CLINICAL CANCER RESEARCH, 2023; 29 (13)
Purpose: This study characterizes intratumoral macrophage populations within baseline melanoma biopsies from patients with advanced melanoma who recei......
期刊: CLINICAL CANCER RESEARCH, 2023; 29 (14)
Purpose: No evidence exists as to whether type 2 diabetes mellitus (T2DM) impairs clinical outcome from immune check -point inhibitors (ICI) in patien......
期刊: CLINICAL CANCER RESEARCH, 2023; 29 (16)
Purpose:Deficiency in homologous recombination (HR) repair of DNA damage is characteristic of many high-grade serous ovarian cancers (HGSC). It is imp......
期刊: CLINICAL CANCER RESEARCH, 2023; 29 (6)
Tumor-associated inflammation (TAI) is a feature of essen-tially all cancers and can confer both tumor-promoting and-suppressive functions. Cancer-ass......